This is a working overview of stability, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2026-07-10 and is reviewed periodically as new material appears.
Dihexa is a synthetic peptide-like compound studied in preclinical research for its reported effects on synaptic growth and cognitive measures in animal models. It is often described as an analog of angiotensin IV, a naturally occurring peptide fragment. The compound has not been approved as a medicine in any major jurisdiction. Most public information comes from laboratory studies, patents, and online vendor listings rather than from large clinical trials. Its scientific status therefore differs from that of an established pharmaceutical.
Research interest in dihexa centers on its ability to promote synapse formation in cultured neurons and in some rodent experiments. These findings have been interpreted as a possible mechanism for learning and memory effects, but the evidence remains preliminary. Independent replication is limited, and study designs vary widely in species, duration, and outcome measures. Human data are scarce, so claims about cognitive enhancement in people are not supported by robust clinical evidence. The gap between laboratory signals and proven clinical benefit is substantial.
Dissolution depends on the peptide’s salt form, purity, and the chosen solvent. Dimethyl sulfoxide is commonly used to prepare concentrated stock solutions, while aqueous buffers may show limited solubility. Sonication or gentle warming can sometimes aid dissolution, but excessive heat may promote degradation. Once in solution, the material is generally kept cold and protected from light. Researchers should verify solubility for each lot rather than assuming uniform behavior across suppliers.
Quality control usually combines reverse-phase high-performance liquid chromatography with mass spectrometry. Chromatography estimates purity and detects related impurities, while mass spectrometry supports molecular identity. Nuclear magnetic resonance can provide additional structural confirmation when needed. Stability data for dihexa are limited, and degradation pathways may depend on pH, temperature, and moisture. Open questions include long-term stability in different formulations and the effect of repeated freeze-thaw cycles on measured purity. Such tests help confirm that a batch matches its label before use.
In laboratory settings, dihexa is typically handled as a lyophilized peptide powder. Appropriate personal protective equipment and a ventilated workspace are standard practices for weighing and transferring research chemicals. Because the compound lacks regulatory approval for clinical use, it should not be given to people. Institutional safety rules and local regulations govern its acquisition, storage, and disposal. Suppliers often provide a certificate of analysis that lists purity, identity, and batch-specific handling notes.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic peptide analog | Derived from an angiotensin IV sequence. |
| Appearance | White to off-white powder | Typical for lyophilized research peptides. |
| Solubility | Soluble in dimethyl sulfoxide; sparingly in water | Exact aqueous solubility depends on salt form and purity. |
| Typical storage temperature | -20 °C or below | Desiccated and protected from light for long-term storage. |
| Common synonyms | Dihexa; N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide | Names vary in catalog listings. |
Discussion of dihexa in online communities sometimes outpaces the scientific record. Anecdotal reports are difficult to verify and may not distinguish effects from placebo or expectation. The absence of approved human data means long-term risks remain unknown. Researchers continue to investigate related compounds and pathways. Open questions include whether animal findings translate to humans and which biological targets matter most. No consensus exists on these points. Current reviews emphasize the need for rigorous clinical research.
Most published work on dihexa consists of preclinical studies using cell cultures or rodents. Reports have described effects on synaptic connectivity and performance on cognitive tasks in some animal models. These findings are generally presented as preliminary and require independent replication. Study designs, doses, and outcome measures vary across experiments, which complicates direct comparison. No large controlled human trials have established efficacy or safety for any medical use. At present, the evidence base is limited.
Regulatory agencies have not approved dihexa as a prescription drug or supplement. In many countries it falls into a gray area when sold for laboratory research. Buyers may encounter products marketed for research use only, which are not intended for human consumption. Purity and identity can vary between suppliers and batches. Certificates of analysis and independent testing are often recommended for research materials. Documentation helps verify what a vial contains.
Dihexa occupies an uncertain regulatory space in many countries. It is not generally listed as an approved therapeutic, and some jurisdictions may treat it as a research chemical, a compounded substance, or an unapproved new drug depending on claims and distribution. Importation can be restricted, and suppliers may require documentation that the material is for laboratory research only. Quality and labeling vary, so buyers should request analytical data, verify lot numbers, and understand local rules. These factors make sourcing and compliance part of the practical context around dihexa.
Lyophilized dihexa is typically stored as a dry powder at or below minus twenty degrees Celsius. Cooler temperatures slow degradation, and desiccant protection limits moisture uptake. Repeated temperature cycling can accelerate breakdown, so aliquoting before storage is common in laboratory practice. Solutions are generally less stable than dry powder and are often kept cold, protected from light, and used within a defined period. Specific stability data for dihexa are limited, and handling recommendations often follow general peptide guidelines rather than compound-specific studies.
Identity and purity of dihexa samples are typically assessed with high-performance liquid chromatography and mass spectrometry. These methods can confirm molecular mass and estimate the presence of impurities. However, a certificate of analysis from a supplier is not a guarantee of independent testing. Researchers often require in-house verification before using a peptide in experiments. For solid samples, appearance, solubility, and chromatographic profile provide additional checks. Nuclear magnetic resonance may be used for structural confirmation when available.
Dihexa is commonly handled as a lyophilized powder in laboratory settings. Storage at -20 °C in a desiccated, light-protected container is typical for peptides. Repeated freeze-thaw cycles can degrade the material, so aliquoting is often recommended. Aqueous solutions may be less stable than organic stocks and should be prepared fresh when possible. Personnel should follow institutional safety procedures and avoid uncontrolled exposure. Because human effects are not well characterized, handling precautions are prudent.
The proposed mechanism of dihexa centers on activation of the hepatocyte growth factor receptor, also called c-Met. Some studies suggest it acts as a mimetic of hepatocyte growth factor, promoting signaling pathways involved in synapse formation. Other work has explored interactions with angiotensin IV pathways, but the exact binding targets remain uncertain. Laboratory findings come mainly from cell cultures and animal models. Whether these mechanisms operate similarly in humans is an open question. Researchers have not established a single, universally accepted mechanism of action.
The proposed mechanism of dihexa involves activation of hepatocyte growth factor and its receptor, c-Met. In cell models, this signaling pathway is associated with dendritic spine formation and synaptic reorganization. Dihexa is described as a stabilized analog of angiotensin IV, which also interacts with related systems. However, the precise binding profile and downstream effects remain incompletely characterized. Most mechanistic evidence comes from in vitro assays and rodent studies rather than human trials.
Laboratory characterization of dihexa typically relies on reverse-phase high-performance liquid chromatography for purity and mass spectrometry for identity. These methods are standard for synthetic peptides and help distinguish the target compound from related impurities or degradation products. Because dihexa is a small peptide-like molecule, it may be susceptible to hydrolysis under certain conditions. Storage recommendations generally emphasize low temperature, dryness, and protection from light. Analytical certificates from suppliers vary in detail, so independent verification can be important for research use.
=== Pharmacokinetics === Nedaplatin is administered in its active form and is removed from the bloodstream by the kidneys to leave the body via the urine. The recommended therapeutic dose of nedaplatin is 80–100 mg/m2 of body surface area. Optimal dosing is determined using measurements of unbound platinum concentrations following intravenous infusion together with an assessment of renal function using creatinine clearance. The dose can be estimated using Ishibashi’s formula: DoseNDP = AUC × CLNDP, where CLNDP = 0.0738 × creatinine clearance + 4.47 The precise mechanism of cellular uptake is not fully understood, and substantially less information is available compared with cisplatin. However, nedaplatin does not interact with the Oct2 transporter or apical multidrug and toxin extrusion (MATE) transporters, which may contribute to its lower accumulation in renal proximal tubules.
== Biological role == Cadmium has no known function in most organisms, and is toxic. Cadmium is considered an environmental pollutant hazardous to living organisms. A cadmium-dependent carbonic anhydrase has been found in some marine diatoms, which live in environments with low zinc concentrations. Exposure to cadmium leads to raised levels in the blood cells for a number of months. In vertebrates cadmium is preferentially absorbed in the kidneys but also in the liver and bones. Up to about 30 mg of cadmium is commonly inhaled throughout human childhood and adolescence. Cadmium is eliminated from the body in very small amounts and mainly through urine resulting in a biological half-life of 20 to 40 years. Cadmium is under research for its potential toxicity to increase the risk of cancer, cardiovascular disease, and osteoporosis.
The original parlor (a remodeled grocery store) at 57th and J Streets in Sacramento remained in business until the mid-1990s. The second Shakey's Pizza Parlor opened in Portland, Oregon, in 1956. Shakey's opened their third parlor in Albany, Oregon, in 1959, which was the first building Shakey's actually owned and the first building to be built in the distinct building style for which Shakey's is known. It now operates as a used bookstore. According to Johnson, Shakey's Pizza engaged in little market research and made most of its decisions on where to locate stores by going where Kinney Shoes opened stores. By the time Johnson sold his interest in 1967, there were 272 Shakey's Pizza Parlors in the United States. The first international store opened in Winnipeg, Manitoba, Canada, in 1968. By 1975, the company had expanded to the Pacific Rim, including Japan (in 1973) and the Philippines (in 1975). By the early 1970s, Shakey's had become popular with families and youth sports groups in Southern California. The long rows of picnic tables end-on-end facilitated large groups. Youth sports teams would go to Shakey's after their weekend games, where the kids could eat pizza and have fun, and the parents could drink beer and socialize. In fact, the advertising motto for Shakey's was "We serve fun at Shakey's... also pizza". One of the features of Shakey's was its large windows between the dining hall and the kitchen. One could order pizza and then watch as the dough was prepared, sauce and toppings added, and then pizza slid into the oven.
In 2020, urea derivative 3 (Table 1) was identified via high-throughput screening (HTS), as a competitive inhibitor of ERAP1 aminopeptidase activity (IC50 = 6.9 μM) with increased selectivity over ERAP2 and IRAP. SAR exploration and docking studies showed that the N-acetylpiperazine carbonyl group was critical for the activity via its zinc-binding group properties.
Sources: en.wikipedia.org
=== Solvation effects === Solvation significantly affects the basicity of amines. N−H groups strongly interact with water, especially in ammonium ions. Consequently, the basicity of ammonia is enhanced by 1011 by solvation. The intrinsic basicity of amines, i.e. the situation where solvation is unimportant, has been evaluated in the gas phase. In the gas phase, amines exhibit the basicities predicted from the electron-releasing effects of the organic substituents. Thus tertiary amines are more basic than secondary amines, which are more basic than primary amines, and finally ammonia is least basic. The order of pKb values (basicities in water) does not follow this order. Similarly, aniline is more basic than ammonia in the gas phase, but ten thousand times less so in aqueous solution. In aprotic polar solvents such as DMSO, DMF, and acetonitrile the energy of solvation is not as high as in protic polar solvents like water and methanol. For this reason, the basicity of amines in these aprotic solvents is almost solely governed by the electronic effects.
==== Rebuilding links with the West ==== In 1999, Libya began secret talks with the British government to normalize relations. In 2001, Gaddafi publicly condemned the September 11 attacks on the US by al-Qaeda, expressing sympathy with the victims and calling for Libyan involvement in the US-led war on terror against militant Islamism. His government continued suppressing domestic Islamism, at the same time as Gaddafi called for the wider application of sharia law. Libya also cemented connections with China and North Korea, being visited by Chinese President Jiang Zemin in April 2002. However, relations with China became strained in May 2006 due to a visit to Tripoli by Taiwanese President Chen Shui-bian. Influenced by the events of the Iraq War, in December 2003, Libya renounced its possession of weapons of mass destruction, decommissioning its chemical and nuclear weapons programs. Relations with the US improved as a result. British Prime Minister Tony Blair visited Gaddafi in March 2004; the pair developed close personal ties. In 2003, Libya paid US$2.7 billion to the families of the victims of the Lockerbie bombing as it was the condition the US and UK had made for terminating the remaining UN sanctions. Libya continued to deny any role in the bombing. In 2009, Gaddafi attempted to strong-arm global energy companies operating in Libya to cover Libya's settlement with the families of the victims of Lockerbie.
The benefits of using heterologous expression here is that it produces large amounts of target receptors of drugs of interest, and is generally inexhaustible, reproducible, and inexpensive. These receptors could then be used in assays to test the effectiveness and specificity of drug binding. Moreover, the produced receptors themselves could be used as therapeutics. They could serve as decoys for toxins or excess signaling molecules, and bind/attenuate these molecules.
9.6 Ca(NO3)2 + 6 (NH4)2HPO4 → Ca9.6(PO4)5.6(HPO4)0.4(OH)1.6 Sintering these non-stoichiometric phases forms a solid phase which is an intimate mixture of tricalcium phosphate and hydroxyapatite, termed biphasic calcium phosphate:
=== Second Trump administration (2025–present) === In January 2025, President Donald Trump revoked Biden's Executive Order 14110 (Executive Order on Safe, Secure, and Trustworthy Development and Use of Artificial Intelligence) by issuing Executive Order 14148 (Initial Rescissions of Harmful Executive Orders and Actions), reflecting his administration's preference for deregulating AI in support of innovation over safeguarding risks. He then issued Executive Order 14179 (Removing Barriers to American Leadership in Artificial Intelligence), which called for development of a national "AI Action Plan" and aimed to strengthen U.S. leadership in AI. In 2025, Congress passed legislation targeting AI-generated deepfakes, the TAKE IT DOWN Act, which prohibits nonconsensual disclosure of AI-generated "intimate imagery", requiring all platforms to remove such content. Lawmakers also reintroduced the CREATE AI Act to codify the National AI Research Resource (NAIRR), which aimed to expand public access to computing resources, datasets, and AI testing environments. Meanwhile, the Department of Commerce also expanded export controls on AI technology, and NIST published an updated set of guidances on AI cybersecurity risks. In March 2025, OpenAI made a policy proposal for the Trump administration to preempt pending AI-related state laws with federal laws. Meta, Google, IBM and Andreessen Horowitz also pressured the government to adopt national rules that would rein in state laws, especially in California.
Sources: en.wikipedia.org
Dihexa is a synthetic peptide-like compound studied in preclinical research. It is often described as an angiotensin IV analog, but it is not an approved medicine. Public information comes mainly from laboratory work and commercial listings.
No major regulatory agency has approved dihexa as a therapeutic product. Human safety and efficacy data are limited. Its sale as a research chemical does not constitute approval for medical use.
Some animal and cell studies report synaptic or cognitive effects, which has led to nootropic framing online. These findings are preliminary and have not been confirmed in robust human trials. The term nootropic is not a regulatory category.
Typical storage is at -20 °C in a desiccated container protected from light. Repeated freeze-thaw cycles are usually minimized to reduce degradation. Specific conditions should follow the supplier’s documentation.